Skip to content

Extended Observational Study Following Fixed-Dose Treatment with Buagafuran Capsule in Generalized Anxiety Disorder

Extended Observational Study Following Fixed-Dose Treatment with Buagafuran Capsule in Generalized Anxiety Disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127544
Enrollment
Unknown
Registered
2026-07-02
Start date
2026-07-03
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder (characterized by pervasive and persistent anxiety that is not confined to, or predominantly associated with, any specific external situation, also known as "free-floating anxiety". The following chief complaints are common: persistent nervousness, tremors, muscle tension, sweating, light-headedness, palpitations, dizziness, and epigastric discomfort. The course of ill

Interventions

Low-dose investigational group:None
High-dose investigational group:None

Sponsors

Beijing Anding Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Subjects who have signed the main trial informed consent form and have received at least one dose of the investigational product during or within the main trial period; 2.Be capable of fully understanding and signing the informed consent form for this extended observational study. 3.Subjects shall have no contraindications to venous blood collection, exhibit normal coagulation function, and be able to cooperate with the additional blood collection procedures scheduled at each visit.

Exclusion criteria

Exclusion criteria: 1.Subjects who have seriously violated the protocols of both the main trial and this observational study; 2.Subjects with severe anemia or coagulation disorders; 3.Other conditions judged by the investigator to render the subject ineligible for enrollment;

Design outcomes

Primary

MeasureTime frame
Adrenocorticotropic Hormone;Plasma levels of Corticotropin-Releasing Factor;Cortisol levels;Omics-related indicators;

Countries

China

Contacts

Public ContactWang Gang

Beijing Anding Hospital Affiliated to Capital Medical University

gangwangdoc@gmail.com+86 10 59303005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026